

13th July 2020

Methodological note for Valneva UK Transfer of Value Disclosure 2019.

Valneva UK is a travel vaccine company. Its fourth year of trading was 2019, within that year it marketed two Prescription Only Medicines, and one Consumer product.

To assist the company, Valneva UK contracted one pharmacist for the participation in a promotional company video. Valneva UK also contracted the Chief Executive of the Encephalitis Society, a UK charity, to support awareness of this misunderstood condition. The Chief Executive of the Encephalitis Society received £420 as an honorarium for speaking on Valneva's behalf at the Annual Conference of the British Global and Travel Health Association (BGTHA) and was recompensed for travel expenses amounting to £180.74 in relation to this engagement. Additionally, Valneva UK paid for travel and accommodation for the Chief Executive to the US amounting to £6574.44 to facilitate a meeting with representatives from Valneva US to discuss licensing of the Encephalitis Society's Japanese Encephalitis patient videos for medical education purposes in the US.

To support medical education in the UK, Valneva UK sponsored a symposium (sponsorship amount £1400) at the Annual Conference of the British Global and Travel Health Association (BGTHA), and supported the Travel Medicine Roadshow of the Faculty of Travel Medicine at the Royal College of Physicians and Surgeons of Glasgow with £2000. A payment for the sponsorship of £1644 to the Royal College of Nursing UK to support the RCN and NaTHNaC Travel Health Conference concludes all payments in 2019.

There were no further contracts undertaken in the calendar year 2019. All of the contractors were paid in pound sterling in England, none of the contractors exceeded VAT thresholds and all were left accountable for their own income tax.

An assessment was made as to the hourly charge of each contract to ensure that the charge was fair market value. Activities were assessed to ensure that contractor input was absolutely necessary for the success of each project. Activities where contractor input was deemed necessary were notified in advance and the contractor could opt in or out of taking part in that activity or project.

Other transfers of value were made to several separate travel health organisations and pharmacies by Valneva UK in 2019. All transfers of value relate to the “Valneva in Partnership” joint working programme. These programmes assist pharmacies and existing travel clinics to offer a comprehensive travel service through marketing and educational support designed to ensure travellers seek appropriate travel health advice before travelling and that they have access to travel services when required. Details of the joint working agreements with each of the 12 organisations, [Raylane Pharmacy Group, Davison (Chemist) Ltd, Whitworths, Phoenix(Rowlands), Burdon Pharmacy Group, Community Pharmacy Lancashire, Wymondham Medical Partnership, Numark, Avicenna, Pharmavaccs, London Travel Clinic Ltd and Clari Health], can be found here: <https://www.valnevauk.com/transparency/>

Valneva UK has no multi-year contracts for individual external contractors. There were no over-the-counter transfers of value or medical device transfers of value for 2019. There were no further contracts, donations, grants or sponsorships made to HCPs or HCO in 2019.

Yours Faithfully,

A handwritten signature in black ink that reads 'Tracy Roost'.

Tracy Roost

Statement for the disclosure of 2019 data during the COVID-19 pandemic in 2020

As part of the pharmaceutical industry's annual disclosure of transfers of value to HCPs, ORDMs and HCOs via the Disclosure UK platform and in order to ensure accuracy of the published data, the ABPI writes to all of the HCPs, ORDMs and HCOs named in companies' disclosure data ahead of its publication on Disclosure UK at the end of June. (Over 20,000 in June 2019.)

Given the unprecedented pressure on the NHS and health care professionals in responding to the COVID-19 pandemic, in April 2020 the ABPI and PMCPA agreed that it would not be appropriate for industry to write to HCPs, ORDMs or HCOs to request that disclosure data be reviewed. Doing so would add additional work for NHS professionals at this time. To avoid this, and in-line with guidance provided by the ABPI, Valneva UK's 2019 transfer of value data has been published on Disclosure UK in aggregate.

Commitment to transparency

The pharmaceutical industry is committed to preserving the integrity of Disclosure UK and transparency in our interactions with HCPs, ORDMs and HCOs. The full disaggregated 2019 has been submitted to Disclosure UK by 31th July.